{"id":"NCT05325853","sponsor":"American Genomics, LLC","briefTitle":"A Study of Safety and the Local Anesthetic Effect of AG-920 Ophthalmic Solution in a Pediatric Population","officialTitle":"A Randomized, Single-Masked, Active-Controlled, Parallel-Group Evaluation of Safety and the Local Anesthetic Effect of Articaine Sterile Topical Ophthalmic Solution (AG-920) in a Pediatric Population","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2022-04-06","primaryCompletion":"2022-05-27","completion":"2022-05-27","firstPosted":"2022-04-13","resultsPosted":"2023-10-25","lastUpdate":"2023-10-25"},"enrollment":61,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"SINGLE","primaryPurpose":"SUPPORTIVE_CARE"},"conditions":["Anesthesia, Local"],"interventions":[{"type":"DRUG","name":"AG-920","otherNames":["articaine"]},{"type":"DRUG","name":"Proparacaine Ophthalmic","otherNames":["Proparacaine"]}],"arms":[{"label":"AG-920","type":"EXPERIMENTAL"},{"label":"Proparacaine","type":"ACTIVE_COMPARATOR"}],"summary":"A Phase 3, randomized, active-controlled, study in pediatric subjects. It is designed to evaluate the safety and anesthetic efficacy of one dose of AG-920 ophthalmic solution compared to Proparacaine Hydrochloride Ophthalmic Solution.","primaryOutcome":{"measure":"The Proportion of Participants in Which an Eye Exam Was Able to be Performed","timeFrame":"Two to four minutes following treatment (last drop) of IMP","effectByArm":[{"arm":"AG-920","deltaMin":30,"sd":null},{"arm":"Proparacaine","deltaMin":30,"sd":null}],"pValues":[]},"eligibility":{"minAge":null,"sex":"ALL","healthyVolunteers":true,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["38647654"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":30},"commonTop":[]}}